◾️HP要約
Combining Alpha DaRT® and Pembrolizumab: Promising Early Results
Prof. Aron Popovtzer of Hadassah Medical Center is leading a clinical study combining Alpha DaRT with pembrolizumab for patients with inoperable head and neck cancer. Currently, pembrolizumab alone offers limited effectiveness—only about 23% respond, and durable responses occur in just 8–10%.
In this new trial, Alpha DaRT is used not to fully irradiate the tumor but to stimulate the immune system by targeting a small tumor region. Most patients are eligible, except those with only small, inaccessible lung metastases.
Early results in 8 patients are encouraging:
• ~75% showed meaningful clinical responses
• ~37.5% achieved complete responses
This far exceeds typical response rates for pembrolizumab alone.
The synergistic effect is likely due to immune activation by Alpha DaRT, which increases activated T cells and dendritic cells while reducing inhibitory immune cells. Importantly, no additional side effects have been observed, even in elderly patients.
手術不能な頭頸部がん患者を対象に、キイトルーダPD-1抗体とAlpha DaRT併用効果が信じられない改善率をもたらしている🍵
◾️HP要約
Combining Alpha DaRT® and Pembrolizumab: Promising Early Results
Prof. Aron Popovtzer of Hadassah Medical Center is leading a clinical study combining Alpha DaRT with pembrolizumab for patients with inoperable head and neck cancer. Currently, pembrolizumab alone offers limited effectiveness—only about 23% respond, and durable responses occur in just 8–10%.
In this new trial, Alpha DaRT is used not to fully irradiate the tumor but to stimulate the immune system by targeting a small tumor region. Most patients are eligible, except those with only small, inaccessible lung metastases.
Early results in 8 patients are encouraging:
• ~75% showed meaningful clinical responses
• ~37.5% achieved complete responses
This far exceeds typical response rates for pembrolizumab alone.
The synergistic effect is likely due to immune activation by Alpha DaRT, which increases activated T cells and dendritic cells while reducing inhibitory immune cells. Importantly, no additional side effects have been observed, even in elderly patients.
投資の参考になりましたか？